LEGEND STRAT (01355) announced that on December 23, 2025, its wholly-owned subsidiary, Jia Yi Global, as the buyer, entered into a sale and purchase agreement with the seller, Ms. Zheng Tong. The seller conditionally agreed to sell, and the buyer conditionally agreed to purchase, the sale shares (representing 100% of the issued share capital of the target company, Ono Hong Kong) and the sale loan for a total consideration of HKD 22 million. Upon completion, the target company will become an indirect wholly-owned subsidiary of LEGEND STRAT, and the group will hold a 37.5% equity interest in Biosyn. The financial performance, assets, and liabilities of the Biosyn Group will be accounted for using the equity method in the consolidated financial statements of the group.
Biosyn is a synthetic biology infrastructure provider specializing in strain design and fermentation process development, offering higher-quality, more convenient, and lower-cost technical services and related products to synthetic biology enterprises, biopharmaceutical companies, and traditional fermentation enterprises seeking industrial upgrades through synthetic biology.
The group believes that the research and development of proprietary rights and technologies related to healthcare and beauty businesses are key to gaining a competitive advantage. The group’s current R&D focus areas include: 1. Type III Collagen-Hyaluronic Acid "Dual Protein" Hydrogel, primarily utilizing hyaluronic acid penetration enhancement technology with recombinant Type III collagen + acetylated hyaluronic acid (AcHA) as composite ingredients to improve transdermal absorption efficiency, achieving immediate filling + long-term regeneration. 2. Hydroxyapatite/Collagen Composite Filler, targeting the substantial market for temporal fillers. 3. Photoactivated Collagen Repair Serum, aiming to develop serums containing thermo/photo-sensitive liposomes that release collagen peptides under specific wavelengths for "device-activated" precision repair. 4. Stem Cell Exosome-Targeted Anti-Aging Therapy, focused on developing freeze-dried exosome microspheres for targeted release + long-term repair.
During the development process, the group identified an opportunity to acquire Biosyn, a synthetic biology infrastructure provider specializing in strain design and fermentation process development. Biosyn has established a comprehensive closed-loop synthetic biology infrastructure, covering design software, vector and strain standard architecture, DNA and strain production platforms, data generation, and process-related reagents and equipment R&D and production. Additionally, Biosyn possesses full DNA de novo synthesis capabilities, core molecular enzyme R&D and production capabilities, and fermentation R&D and production capabilities for proteins, small molecules, and composite products from pilot to medium-scale trials.
The group believes that acquiring an equity stake in Biosyn will secure access to its services, enhance the efficiency of its own R&D projects, reduce R&D costs, and accelerate the commercialization of R&D achievements. To the best of the directors’ knowledge after reasonable inquiries, all existing shareholders and management of Biosyn are independent third parties. Upon completion of the acquisition, the group will have the right to nominate and replace up to two directors on Biosyn’s current five-member board.